



JAMES F. EWING



PARTNER

JFEWING@FOLEY.COM

111 HUNTINGTON AVENUE SUITE 2600
BOSTON, MA 02199-7610
(617) 342-4088

James F. Ewing is a partner with Foley & Lardner LLP. Dr. Ewing is vice chair of the Chemical, Biotechnology & Pharmaceutical Practice and a member of the Life Sciences, Food and Nanotechnology Industry Teams.

Dr. Ewing primarily advises pharmaceutical, biotechnology, and nutraceutical clients. In the pharmaceutical and biotechnology sectors, Dr. Ewing works with companies engaged in drug discovery to develop and produce peptide and small molecule therapeutics, encompassing such technologies as computationally assisted drug design, immunology and vaccine technologies, stem cell technologies, neurobiology, drug delivery, gene therapy technologies, nanobiology technologies and biomedical devices.

Dr. Ewing's experience includes:

- Advising clients on the creation and development of patent portfolios, collaborative research, licensing of technology, raising money through venture capital and other financial transactions, and enforcement of their intellectual property rights
- Performing due diligence investigations for private and public financings and M&A transactions
- Providing patent invalidity, freedom to operate and non-infringement opinions
- Initiating and defending patent interference proceedings for clients
- Counseling nutraceutical companies engaged in the development of natural herbal remedies and dietary supplements

Dr. Ewing has more than 15 years of experience as a research biochemist in academic medical universities and drug discovery companies. He is the author of numerous peer-reviewed scientific articles and invited



reviews on a variety of scientific topics. Dr. Ewing has worked in several Massachusetts-based drug discovery companies with interest in the development of new cardiovascular, reproductive, gastrointestinal and central nervous system therapeutics, as well as antibiotics. Dr. Ewing has been selected for inclusion in the 2005 - 2009 *Massachusetts Super Lawyers-Rising Stars*® editions for his work in intellectual property.

Dr. Ewing's selected legal publications include:

- "Knowledge generation, integration key in drug development strategies," *Mass High Tech*, James F. Ewing, John M. Garvey, and Michel Morency, July 6, 2004
- "Patent strategy can bring collaboration revenues," *Mass High Tech*, Michel Morency, James F. Ewing, Chinh Pham, and John M. Garvey, February 2, 2004
- "How to get licensees to help you monitor the market for infringers," *Mass High Tech*, Michel Morency, James F. Ewing, and John M. Garvey, October 13, 2003

Dr. Ewing is a graduate of Union College (B.S., with honors), Albany Medical College (M.S. and Ph.D.) and Suffolk University Law School (J.D., *cum laude*).

He is a member of the Massachusetts Bar Association and is admitted to practice in the state of Massachusetts and before the USPTO.



JAMES C. CHAPMAN



PARTNER

JCHAPMAN@FOLEY.COM

975 PAGE MILL ROAD
PALO ALTO, CA 94304-1013
(650) 251-1120

James C. Chapman is a partner with Foley & Lardner LLP where he focuses on securities law, venture capital, mergers and acquisitions, and international business transactions. Mr. Chapman has more than 20 years experience in corporate and securities law and has been involved in over 200 mergers, acquisitions, and financing transactions. These transactions have included public offerings, private placements, debt financings, venture capital transactions, stock sales, asset sales, mergers, reorganizations, and recapitalizations. He is a member of the firm's Private Equity & Venture Capital and Transactional & Securities Practices, as well as the Emerging Technologies Industry Team.

Mr. Chapman also has a significant background in international transactions, particularly dealing with China and Chinese-related companies. These transactions include both assisting Chinese companies invest and raise capital in the U.S. and helping U.S. firms make investments and operate in China. From the media industry to the pharmaceutical industry, Mr. Chapman has been engaged in working with clients on numerous China-U.S. transactions and matters.

Prior to joining Foley, Mr. Chapman established the Nixon Peabody LLP Silicon Valley office and served as its managing partner for two and a half years. He also had a major role in the development of Nixon Peabody's China practice.

His recent engagements include:

- Represented Ananias World Fund in connection with the formation of a multi-billion dollar credit and collateral enhancement fund
- Represented the Band of Angels in connection with the formation of its seed investment fund



- Represented Sierra Asia Partners, a China focused investment bank, in connection with its world-wide reorganization
- Represented Oryx Advanced Materials in connection with the termination of its joint venture in China
- Represented China-based Senodia Technologies in connection with its bridge financing
- Represented Bellatore LLC in connection with the acquisition of the financial management business of Nationwide Insurance
- Represented Ferrari North America in connection with the sale of its California dealership
- Represented Zippi Networks in connection with an \$11 million equity line of credit with Palm Valley Capital
- Represented Bellatore, Inc., in connection with its \$11 million Series A financing
- Represented a developer of distributed energy monitoring software in connection with its \$3 million bridge financing
- Represented Singapore telecommunications company, as co-counsel with King & Wood, in a Chinese joint-venture
- Represented Business Finance Capital Corporation in connection with its merger with First Community Bank
- Represented Austin Glen Core LLC in connection with its formation and structure of its real estate acquisition fund
- Represented TAS Commerce Fund I in connection with its formation and structure of its Asia investment fund
- Represented Northwest Fund I in connection with the sale of membership units

Mr. Chapman was named to the *Northern California Super Lawyers* list for his securities & corporate finance, mergers & acquisitions and business/corporate work



(2004-2008). He also was recognized as one of "Silicon Valley's Top Attorneys" by *San Jose Magazine* (2003-2007).

Mr. Chapman earned both his law degree (J.D.) and his master's degree (M.B.A.) from Santa Clara University. He is a graduate of Catholic University of America (B.A.).

Mr. Chapman is admitted to practice in California.

His recent articles and publications include:

- "Intellectual Property Protection in China- Building the Proper Foundation," Nixon Peabody LLP, May 2009
- "M&A in China – Ten Strategies For Successful Cross-Border Transactions," *Asian Counsel*, September 2008
- "The Road to China: Ten Key Lessons for doing Business in China," *The Licensing Journal*, Vol.28, No. 7
- "In the Eye of a Hurricane - Duties of Directors in a Turbulent Environment," *Software Developer's Forum Newsletter*, August 2008
- "China IPOs—The Era of Transition," *Asian Counsel*, May 2008
- "Trends in Mergers & Acquisitions," *Band of Angels Newsletter*, March 2008
- "The Road to China: Ten Key Lessons on Doing Business in China," Nixon Peabody LLP, March 2008
- "Traps for the Unwary: The Application of the United States Foreign Corrupt Practices Act in China," Nixon Peabody LLP, March 2008
- "Trends in IPOs," *Corporate Counselor*, September 2007
- "Trends in IPOs," *Band of Angels Newsletter*, September 2007



- "Private Equity in China," *Nixon Peabody Private Equity Alert*, July 2007
- "Entering China: Legal Recommendations for Ensuring Success in a Foreign Market," *San Jose Magazine*, Vol. 9, Issue 10, October 2006
- "Mergers and Acquisitions: Integration, the Key to Success," *Bay Area Lawyer*, Vol. 2, Issue 4, July 2006
- "Entrepreneurialism 101: Five Key Characteristics of Successful Entrepreneurs," *Bay Area Lawyer*, Vol. 2, Issue 3, May 2006
- "Life and Death on the Corporate Battlefield: Advice to Management Employees Departing to Form New Companies," *Bay Area Lawyer*, Vol. 2, Issue 2, March 2006
- "Don't Turn a Dream Into a Nightmare: The Five Most Common Mistakes Entrepreneurs Make When Selling Their Businesses," *Bay Area Lawyer*, Vol. 2, Issue 2, March 2006
- "Minding Your Client's Business: Becoming an Indispensable Resource— Five Tips on Delivering for Business Clients," *Bay Area Lawyer*, Vol. 2, Issue 1, January 2006



GREG B. SCOTT



PRESIDENT AND FOUNDER

CHINABIO® LLC
BIOTECH VC PLAZA
ZHANGJIANG HI-TECH PARK
780 CAILUN ROAD, SUITE 822
PUDONG, SHANGHAI 201203

Greg B. Scott is an entrepreneur, angel investor and business advisor who has helped launch over thirty life science companies in the U.S. and China.

Mr. Scott founded ChinaBio® LLC in January 2007 to identify and develop early stage life science companies in China, which has now grown into a 15 person consulting and market research firm helping US and European companies identify potential partners and novel technologies in China. ChinaBio® also organizes several investment conferences in China each year, and held its second annual international partnering conference last month in Suzhou, which attracted 558 attendees from 23 countries.

In his spare time, Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 32 biotechnology and medical device companies since 2005, and executive editor of the *ChinaBio® Today* newsletter. He lives and works in Shanghai but visits the US several times a year to enjoy California's blue sky and sandy beaches.



GUANG YANG



ASSOCIATE DIRECTOR,
DISCOVERY TECHNOLOGY

GLAXOSMITHKLINE (CHINA) R&D Co., LTD.
898 HALEI ROAD
ZHANGJIANG HI-TECH PARK
PUDONG, SHANGHAI 201203

Guang Yang is the associate director in discovery technology for GlaxoSmithKline (China) R&D Co., Ltd.

Dr. Yang has nearly 15 years experience in the pharmaceutical industry. He specializes in small molecule drug target validation and assay technology development. He has successfully led multiple discovery programs from target selection to candidate compound identification and validation for various disease indications (eg. cancer, RA, asthma, metabolic syndrome, anti-infectious, etc.) in several global pharmaceutical companies from 1997 to 2008.

Dr. Yang joined GSK R&D China in 2008 to facilitate the establishment of platform technology function in support of GSK's local drug discovery efforts. Recently he expands his role in GSK R&D China focusing on the development and commercialization of transformative drugs in China and the region.

Dr. Yang received his Ph.D. in biochemistry from the University of Maryland, his M.S. in organic chemistry from Bucknell University in Pennsylvania, and his B.S. in polymer chemistry from the University of Science & Technology of China.

Dr. Yang works and lives in Shanghai. During his spare time, he enjoys traveling with his family to explore the world. He is fluent in Chinese and English.